| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/14/2005 | WO2005062874A2 Compounds and compositions for delivering active agents |
| 07/14/2005 | WO2005062852A2 COMPOSITIONS CONTAINING d-TOCOPHEROL COMPOUND POLYBASIC ACID PARTIAL ESTERS |
| 07/14/2005 | WO2005062851A2 Indole-3-propionamide and derivatives thereof |
| 07/14/2005 | WO2005062828A2 New compounds useful as metal chelators |
| 07/14/2005 | WO2005062824A2 Anti-hypercholesterolemic compounds |
| 07/14/2005 | WO2005062782A2 Non-animal product containing veterinary formulations |
| 07/14/2005 | WO2005062761A2 Stabilized prednisolone sodium phosphate solutions |
| 07/14/2005 | WO2005062748A2 Bicyclic carbohydrate compounds useful in the treatment of infections caused by herpesviridae |
| 07/14/2005 | WO2005062739A2 S-allylmercaptocysteine prodrugs and methods of treatment |
| 07/14/2005 | WO2005062722A2 Fexofenadine containing pharmaceutical formulation |
| 07/14/2005 | WO2005062718A2 Methods of administering 3,3,14,14 tetramethyl hexadecane 1,16 dioic acid |
| 07/14/2005 | WO2005056043A3 Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune |
| 07/14/2005 | WO2005053691A3 Nicotine delivery product and method for producing it |
| 07/14/2005 | WO2005051946A3 Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| 07/14/2005 | WO2005051920A3 Specific antagonist for both e- and p-selectins |
| 07/14/2005 | WO2005049579A3 Immobilized n-substituted tricyclic 3-aminopyrazoles for the identification of biomolecular targets |
| 07/14/2005 | WO2005046674A3 Antibacterial compositions |
| 07/14/2005 | WO2005046612A3 Hydroxy piperidine derivatives to treat gaucher disease |
| 07/14/2005 | WO2005046584A3 Stimulation of hair growth by ginkgo biloba flavanoids |
| 07/14/2005 | WO2005046360A3 Carbohydate and electrolyte replacement composition |
| 07/14/2005 | WO2005045038A8 RNA INTERFERENCE MEDIATED INHIBITION OF GPRA AND AAA1 GENE EXPRESSION USING SHORT NUCLEIC ACID (siNA) |
| 07/14/2005 | WO2005044175A3 Desensitization of complement activation using monocyte/macrophage inhibitory compounds |
| 07/14/2005 | WO2005043971A3 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| 07/14/2005 | WO2005041920A3 Pharmaceutical licofelone formulation |
| 07/14/2005 | WO2005040142B1 Novel keto-oxadiazole derivatives as cathepsin inhibitors |
| 07/14/2005 | WO2005040073A3 Solid phase synthesis of 3-aryl-2- indolylcarboxylic acids |
| 07/14/2005 | WO2005039597A3 Immunemodulating oligosaccharides |
| 07/14/2005 | WO2005039320A3 Composition for the activation of the immune system |
| 07/14/2005 | WO2005037347A3 Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents |
| 07/14/2005 | WO2005037187A3 High affinity ligands for influenza virus and methods for their production |
| 07/14/2005 | WO2005035779A3 Method |
| 07/14/2005 | WO2005035514A3 Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| 07/14/2005 | WO2005034859A3 Extended release formulations of opioids and method of use thereof |
| 07/14/2005 | WO2005034837A3 7H-IMIDAZO [1,2-α] PYRAZIN-8-ONE COMPOUNDS AS ION CHANNEL MODULATORS |
| 07/14/2005 | WO2005031000A3 Treating neuropathic pain with neuropeptide ff receptor 2 agonists |
| 07/14/2005 | WO2005030186A3 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation |
| 07/14/2005 | WO2005030150A3 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF |
| 07/14/2005 | WO2005030109A3 Regimen for the administration of rifamycin-class antibiotics |
| 07/14/2005 | WO2005026324A3 Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog |
| 07/14/2005 | WO2005023990A3 Trans-splicing mediated photodynamic therapy |
| 07/14/2005 | WO2005023761A3 Cytokine inhibitors |
| 07/14/2005 | WO2005020877A3 Use of biotin or a biotin derivative for lightening skin and treating age spots |
| 07/14/2005 | WO2005018623A8 Parenteral and oral formulations of benzimidazoles |
| 07/14/2005 | WO2005017185A3 HEPATOCYTE NUCLEAR FACTOR 4α MODULATOR COMPOUNDS |
| 07/14/2005 | WO2005013955A8 Topical composition comprising terbinafine and hydrocortisone |
| 07/14/2005 | WO2005013888A3 Compounds, compositions and methods |
| 07/14/2005 | WO2005011689A3 Treatment of inflamed joints |
| 07/14/2005 | WO2005006890A3 Foods, beverages, condiments, spices and salad dressings with specialized supplements |
| 07/14/2005 | WO2005002508A3 Macromolecular platinum chelates |
| 07/14/2005 | WO2005000212A8 Method for treating diseases using hsp90-inhibiting agents in combination with nuclear export inhibitors |
| 07/14/2005 | WO2004108960A3 Methods for predicting drug efficacy in patients afflicted with hypertension |
| 07/14/2005 | WO2004108085A3 Methods for the protection of memory and cognition |
| 07/14/2005 | WO2004103394A3 Method and compositions for nerve regeneration |
| 07/14/2005 | WO2004098528A3 Pyrazole-amine compounds useful as kinase inhibitors |
| 07/14/2005 | WO2004091537B1 Process for making gel films |
| 07/14/2005 | WO2004058770A8 Triptolide derivatives and their use |
| 07/14/2005 | WO2004047838A2 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents |
| 07/14/2005 | WO2004042021A3 Method for inhibiting calcium-induced cell death |
| 07/14/2005 | WO2004024745A3 Complexes of 6.alpha. 9.alpha. - difluoro - 17. alpha. - [ (2 - furanylcarbonyl) oxy] - 11.beta. -hydroxy - 16- .alpha. -methyl - 3oxo- androsta- 1,4 -diene - 17 .beta. -carbothioic acid s-fluoromethyl ester |
| 07/14/2005 | WO2004000016A9 Antimicrobial compositions, products and methods employing same |
| 07/14/2005 | WO2003059294A3 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/14/2005 | US20050155087 Method of screening compounds |
| 07/14/2005 | US20050154537 Methods, program products, and systems for single and multi-agent dosing and other related methods |
| 07/14/2005 | US20050154232 Nitrosation of the diphenylamine with an alkali metal nitrite in an acidic medium; the nitrosodiphenylamines increase the bioavailability of endothelial nitrogen monoxide; the diphenylamines are used as antioxidants and free radical scavengers; insulin resistance |
| 07/14/2005 | US20050154231 Tamsulosin derivative |
| 07/14/2005 | US20050154230 Urea derivatives |
| 07/14/2005 | US20050154215 Extraction from Zanthoxylum naranjillo leaves; nuclear magnetic resonance; for treatment of Chaga's disease |
| 07/14/2005 | US20050154213 Novel boronate esters |
| 07/14/2005 | US20050154202 Substituted aryl amides |
| 07/14/2005 | US20050154201 Via cyclocondensation of aryl/heteroaryl aldehyde with 1,3-acetonedicarboxylic acid |
| 07/14/2005 | US20050154190 compounds obtained by the screening of the present invention are useful as agents for the prevention/treatment of, for example, neurodegenerative diseases, immunological diseases, edema, acid indigestion, etc. |
| 07/14/2005 | US20050154165 Ph-sensitive polymer |
| 07/14/2005 | US20050154066 Antiaging composition |
| 07/14/2005 | US20050154064 Dietetics; use in treatment of obesity, hepatic steatosis, or fatty liver, for reducing body weight, modulating body lipid metabolism, and reducing food intake |
| 07/14/2005 | US20050154062 Substituted chiral allosteric hemoglobin modifiers |
| 07/14/2005 | US20050154061 peroxisome-proliferator-activated receptor (PPAR)-delta agonist; 2-[4-[[[2-[(2,4-Dichlorophenyl)amino]-2-oxoethyl]cyclohexylamino]methyl]-2-methylphenoxy]-2-methylpropanoic acid; cardiovascular disorders, dyslipidaemias or restenosis; improves HDL/LDL cholesterol ratio; side effect reduction |
| 07/14/2005 | US20050154060 Anti-inflamatory inhalation pharmaceutical composition |
| 07/14/2005 | US20050154059 Method of treating type III hypersensitive reaction-related diseases and conditions by using conjugated linoleic acid |
| 07/14/2005 | US20050154058 additives in food, cosmetic, pharmaceutical preparations; regioselective esterification of hydroxytyrosol (or oleuropein, oleuropein aglycones) by acylating agent (organic acid or ester) in presence of easily eliminated catalysts; more soluble in lipids; high chemical yields; high potency antioxidant |
| 07/14/2005 | US20050154057 Crystalline form of y-aminobutyric acid analog |
| 07/14/2005 | US20050154056 Inhibitors of HCV NS5B polymerase |
| 07/14/2005 | US20050154053 Methods and compositions for immunomodulation |
| 07/14/2005 | US20050154052 Novel crystalline forms of (s)-citalopram oxalate |
| 07/14/2005 | US20050154050 Compound |
| 07/14/2005 | US20050154049 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis |
| 07/14/2005 | US20050154048 cysteine proteases, cathepsin K; bone metabolic enzymes inhibitor; bone resorption process; anticarcinogenic; 5-[1-(hydroxyimino)ethyl]-2-thiophenecarboxylic acid 2-[[(9H-fluoren-9-yl)methoxy]carbonyl]hydrazide; esterification and coupling with diamine compounds of thiophenecarboxylic acid derivatives |
| 07/14/2005 | US20050154047 Exert the beneficial effects of melatonin including anti-oxidation, sedation, anesthesia, protection of organs to chemical, infectious and cardiovascular damage, and can be administered in a water-based vehicle |
| 07/14/2005 | US20050154046 methods of treating inflammatory-related diseases associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines. The method typically comprises administration of one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof |
| 07/14/2005 | US20050154045 E.g., N-[4-(2-Thienyl)phenyl]-1-azabicyclo[2.2.2]octane-3-carboxamide hydrochloride; treatment of impairments of perception, concentration, learning and/or memory |
| 07/14/2005 | US20050154044 Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| 07/14/2005 | US20050154043 Heterocyclic compounds useful as growth hormone secretagogues |
| 07/14/2005 | US20050154042 N-alkyl pyrroles as HMG-CoA reductase inhibitors |
| 07/14/2005 | US20050154041 Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist |
| 07/14/2005 | US20050154040 Nitrogen-containing heteroaryl derivatives |
| 07/14/2005 | US20050154039 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 07/14/2005 | US20050154038 bicyclo[2.2.2]-oct-1-yl-1,2,4-triazoles; type 2 diabetes, lipid disorders, obesity, atherosclerosis, metabolic syndrome, hyperglycemia, insulin resistance; increase insulin sensitivity in muscle, liver and adipose tissue by correction of the elevated plasma levels of glucose without causing hypoglycemia |
| 07/14/2005 | US20050154037 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 07/14/2005 | US20050154036 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 07/14/2005 | US20050154035 Methods of using zonisamide as an adjunctive therapy for partial seizures |
| 07/14/2005 | US20050154034 Improve the safety anti-epilepsy therapy, reducing the side effect of drug, by informing and monitoring the patient by laboratory test, medical evaluation; adjusting the dosages |